Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHEMET vs CUVRIOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
Treatment of acute and chronic lead poisoning,Treatment of mercury poisoning,Treatment of arsenic poisoning,Diagnostic chelation challenge test
Treatment of Wilson disease in patients intolerant to penicillamine,Off-label: treatment of copper overload in other conditions
10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.
300 mg subcutaneously once daily.
Terminal elimination half-life: 1.6–3.5 hours (mean 2.1 h) in adults with normal renal function; prolonged in renal impairment (up to 20 h).
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
Metabolized in liver to disulfide dimers; undergoes enterohepatic circulation; primarily excreted renally as metabolites and unchanged drug.
Metabolized mainly by conjugation and oxidation; minor involvement of CYP450 enzymes.
Renal: 80–90% as unchanged drug and metabolites (primarily as chelated complexes); biliary/fecal: <10%.
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
Approximately 80% bound to plasma proteins, primarily albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
0.5–0.8 L/kg, indicating distribution mainly in extracellular fluid; limited intracellular penetration.
Vd is approximately 0.2–0.3 L/kg, indicating distribution largely confined to plasma and extracellular fluid.
20–40% after oral administration due to first-pass metabolism and limited absorption.
Not administered orally due to poor absorption; bioavailability by oral route is negligible.
GFR 50-80 m L/min: same dose every 12 hours. GFR 10-49 m L/min: same dose every 24 hours. GFR <10 m L/min: same dose every 48 hours.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No specific recommendations; caution in severe hepatic impairment (Child-Pugh C) due to potential toxicity.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
Children >1 year: 10-20 mg/kg/dose orally every 8 hours for 5 days; maximum 1250 mg/dose.
Safety and efficacy not established in pediatric patients.
Consider starting at lower end of dosing range (10 mg/kg) due to potential renal impairment; adjust per renal function.
No specific dose adjustment recommended; clinical studies included a limited number of patients aged ≥65 years, with no overall differences in safety or efficacy observed.
None
None
May cause nephrotoxicity; monitor renal function,May cause hypersensitivity reactions, including fever, rash, and anaphylaxis,Monitor for neutropenia; obtain CBC before and during therapy,Use caution in patients with hepatic impairment or glucose-6-phosphate dehydrogenase (G6PD) deficiency,May chelate essential minerals (e.g., zinc, copper); monitor levels with prolonged use,Not recommended for routine use in asymptomatic lead poisoning with low blood lead levels
Monitor for iron deficiency due to copper chelation,May cause lupus-like syndrome,Monitor liver function tests,Use with caution in patients with renal impairment
Hypersensitivity to dimercaprol or any component of the formulation,Hepatic failure (except severe heavy metal poisoning),Concurrent use with iron (increases nephrotoxicity); avoid iron therapy within 24 hours,Pregnancy (if not life-saving indication due to risk of teratogenicity),Peanut allergy (formulation contains peanut oil)
Hypersensitivity to trientine or any component,Rheumatoid arthritis (due to potential exacerbation of symptoms),Use in pregnancy only if clearly needed
No specific food interactions reported. However, due to gastrointestinal side effects (nausea, vomiting), it is advisable to maintain small, frequent meals. Avoid alcohol.
Take CUVRIOR on an empty stomach: at least 1 hour before meals or 2 hours after meals. Avoid high-copper foods such as chocolate, nuts, shellfish, liver, mushrooms, and whole grains. Avoid dairy products and milk within 1 hour of dosing as calcium may reduce absorption. Iron supplements and zinc supplements should be taken at least 2 hours apart from CUVRIOR.
FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimesters: No specific teratogenicity, but may cause anemia in fetus due to maternal chelation of essential metals. Avoid use unless clearly needed.
CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Copper deficiency from aggressive chelation may increase teratogenic risk; therefore, maintaining copper levels within the therapeutic range is critical. First trimester: highest risk for malformations; second and third trimesters: risk of fetal copper deficiency and impaired development if maternal copper is overchelated.
No human data on excretion in breast milk. M/P ratio unknown. Caution due to potential for infant exposure and chelation of trace elements; consider benefit-risk. Avoid breastfeeding during therapy and for 2 weeks after last dose.
It is unknown whether trientine is excreted in human milk. Caution should be exercised when administered to a nursing woman. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No specific dose adjustments recommended for pregnancy. Increased plasma volume in pregnancy may alter pharmacokinetics, but studies not performed. Use lowest effective dose; monitor therapeutic response and toxicity closely.
Physiologic changes in pregnancy (increased plasma volume, enhanced renal clearance) may reduce trientine concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic data in pregnancy are lacking. The goal is to maintain copper levels within the therapeutic range; doses may need to be increased to prevent under-chelation, but careful monitoring is essential to avoid over-chelation and copper deficiency. Dose adjustments should be individualized based on serum copper levels and clinical response.
Chelation therapy with dimercaprol (CHEMET) should be initiated within 4 hours of arsenic or mercury exposure for maximal efficacy. Administer only via deep intramuscular injection, never intravenously. Monitor renal function and urine output closely, as dimercaprol can cause nephrotoxicity. Alkalinize urine to p H 7.5-8.5 to decrease renal precipitation of metal-drug complexes. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolysis. Contraindicated in patients with peanut allergy (vehicle is peanut oil).
CUVRIOR (trientine hydrochloride) is a copper-chelating agent used for Wilson disease. Monitor urinary copper excretion and serum free copper (non-ceruloplasmin bound) to guide dosing. Avoid concurrent use with zinc supplements or other chelators due to antagonism. Administer on an empty stomach (1 hour before or 2 hours after meals) and separate from other medications by at least 1 hour. Iron deficiency anemia can occur due to copper depletion; check iron studies periodically. Neurological worsening may occur early in therapy; use lower starting doses in patients with neurological symptoms.
This medication is given as a shot into a muscle, usually in the buttock. It may cause pain at the injection site.,You may experience a metallic taste, nausea, vomiting, headache, or burning sensation in the mouth or throat.,Drink plenty of fluids unless otherwise instructed to help flush metals from your body.,Avoid alcohol during treatment and for at least 48 hours after the last dose.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or dark urine immediately.
Take CUVRIOR on an empty stomach, at least 1 hour before or 2 hours after meals.,Separate CUVRIOR from other medications, supplements, or antacids by at least 1 hour.,Do not take CUVRIOR with milk, dairy products, or iron supplements.,Report any new or worsening neurological symptoms, such as tremors, difficulty speaking, or trouble walking, to your doctor immediately.,Regular blood tests are required to monitor copper levels and liver function.,Do not stop taking CUVRIOR abruptly; consult your doctor before making any changes.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHEMET vs CUVRIOR, answered by our medical review team.
CHEMET is a Chelating agent that works by Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.. CUVRIOR is a Chelating Agent that works by CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHEMET and CUVRIOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHEMET is: 10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.. The standard adult dose of CUVRIOR is: 300 mg subcutaneously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHEMET and CUVRIOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHEMET is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimes. CUVRIOR is classified as Category C. CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.